Epidemiology of Community Acquired Pneumonia in North Israel

Sponsor
HaEmek Medical Center, Israel (Other)
Overall Status
Unknown status
CT.gov ID
NCT00390819
Collaborator
(none)
100
1

Study Details

Study Description

Brief Summary

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality and is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

Aim of study: To identify common pathogens causing CAP in hospitalized patients in north Israel.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality.

    CAP is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

    CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are different, treatment approach is also different. The main obstacle is absence of adequate diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is not always appropriate. Giving the right therapy at the right time is of major importance since early start of correct treatment is linked to morbidity and mortality of patients. For prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent causing pathogens according to age groups and other demographic characteristics, is essential.

    Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical Center, there is no characteristic information regarding causing pathogens. Lacking this data, might result in selecting inadequate treatment.

    Material & Methods:

    We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the diagnosis of CAP, in order to make the study results statistically significant.

    In addition to demographic and clinical data, following tests will be performed:
    1. Blood cultures

    2. Sputum

    3. PCR - throat culture to the following pathogens:

    • Mycoplasma pneumoniae

    • Chlamydia pneumoniae

    • Legionella

    • Adenovirus

    • Influenza A

    • Influenza B

    • RSV

    • Metapneumovirus

    • Parainfluenza

    • Pneumococcal antigen in urine

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Defined Population
    Time Perspective:
    Prospective
    Official Title:
    Epidemiology of Community Acquired Pneumonia in North Israel
    Study Start Date :
    Nov 1, 2006

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Community acquired pneumonia

      • Hospitalization

      Exclusion Criteria:
      • Immunocompromised patients

      • Patients under chemotherapy treatment

      • Patients under steroids treament

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Ha'Emek Medical Center Afula Israel 18101

      Sponsors and Collaborators

      • HaEmek Medical Center, Israel

      Investigators

      • Principal Investigator: Fahmi Shibli, M.D., Ha'Emek Medical Center, Afula, Israel

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00390819
      Other Study ID Numbers:
      • 131074
      First Posted:
      Oct 20, 2006
      Last Update Posted:
      Oct 20, 2006
      Last Verified:
      Oct 1, 2006
      Keywords provided by , ,
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Oct 20, 2006